Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET
Company Participants
Francesca Nolan - Executive Director of Investor Relations and Corporate Communications
Douglas Ingram - President and Chief Executive Officer
Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head of Research & Development
Dallan Murray - Executive Vice President and Chief Customer Officer
Ian Estepan - Executive Vice President and Chief Financial Officer
Conference Call Participants
Gena Wang - Barclays Capital
Tazeen Ahmad - Bank of America
Gil Blum - Needham & Company
Kostas Biliouris - BMO Capital Markets
Neena Bitritto-Garg - Deutsche Bank
Tim Lugo - William Blair
Uy Ear - Mizuho Securities
Ritu Baral - TD Cowen
David Hoang - Citigroup
Mike Ulz - Morgan Stanley
Richard Miller - Cantor Fitzgerald
Anupam Rama - J.P. Morgan
Operator
Good afternoon and welcome to the Sarepta Therapeutics Fourth Quarter and Full-Year 2023 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, today's program is being recorded.
At this time, I'll turn the call over to Francesca Nolan, Executive Director, Investor Relations and Corporate Communications. Please go ahead.
Francesca Nolan
Thank you, Shannon. And thank you all for joining today's call. Earlier this afternoon, we released our financial results for the fourth quarter and full-year 2023. The press release is available on our Web site at sarepta.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining us on the call today are Doug Ingram; Ian Estepan; Dallan Murray; and Dr. Louise Rodino-Klapac. After our formal remarks, we'll open the call for Q&A.
I'd like to note that, during this call, we will be making a number of forward-looking statements. Please take a moment to review our slide on the webcast which contains our forward-looking statements. These forward-looking statements involve risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements, and any such risks can materially and adversely affect the business, the results of operations, and trading prices for Sarepta's common stock. For a detailed description of applicable risks and uncertainties, we encourage you to review the Company's most recent annual quarterly report on Form 10-K filed with the SEC, as well as the Company's other SEC filings.
The Company does not undertake any obligation to publicly update its forward-looking statement, including any financial projections provided today based on subsequent events or circumstances.